Integrated Analysis of Somatic Genomic Mutations and Antigen Presentation as Predictive Biomarkers for Combination Immunotherapy in Kidney Cancer

Abstract

The proposal seeks to integrate various genomic biomarkers to better predict response to immune checkpoint inhibitor therapy in patients with renal cell carcinoma. Our proposal seeks to establish HLA diversity as a key predictive marker for response to immunotherapy, and also combine this predictive marker with other genomic factors to better refine its predictive capability. In the annual report period, we have completed major task 1 as referenced in specific aim 1 and are actively continuing to work on completing other major tasks in specific aim 1and 2. We also published our preliminary findings on HLA diversity in molecular cancer research, demonstrating the critical role of HLA diversity.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2021
Accession Number
AD1166366

Entities

People

  • Chung-Han Lee

Organizations

  • Memorial Sloan Kettering Cancer Center

Tags

DTIC Thesaurus Topics

  • Biological Markers
  • Biomedical Research
  • Cancer
  • Combination Therapy
  • Department Of Defense
  • Diseases And Disorders
  • Electronic Mail
  • Immunotherapy
  • Inhibitors
  • Kidney Cancer
  • Maryland
  • Medical Personnel
  • Mutations
  • Neoplasms
  • New York
  • Parkinson'S Disease
  • Professional Development
  • Technology Transfer
  • Therapy

Fields of Study

  • Biology

Readers

  • Molecular and genetic basis of cancer.
  • Oncology
  • Technical Research and Report Writing.

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech